India, Aug. 26 -- The following biotech stocks reached a 52-week high on August 25, 2026, driven by key catalysts including positive clinical trial results or the issuance of quarterly reports.
Generate Biomedicines Inc. (GENB)
Generate Biomedicines is a clinical-stage generative biology company that discovers new therapeutics using its proprietary Generate Platform. The company saw a new 52-week high on Tuesday, reaching $22.67 in the intraday trade after climbing over 15%.
For the second quarter of 2026, the company sustained a wider net loss of $67.3 million, compared to $59.7 million in the previous year. Following a Nasdaq debut in February, revenues reduced to $6.3 million from $10.1 million in 2025, as expenditure increased for jo...